Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


RWD/RWE Programming & Reporting Standards: Utilising OMOP Standards 

Real-world data is a rich source of information that we are now starting to use for regulatory submissions. However, as the collection and validation of this data is less standard and restricted than clinical trial data, it poses a lot of challenges that we, as an industry, are not used to. Working with missing data, different analysis techniques, different dictionaries and data models poses challenges for our clinical and statistical programmers.

During this Community forum we will dive into this and give examples of mapping and data handling in two ways (OMOP to SDTM and source/SDTM to OMOP). We will explore the challenges of mapping to and from OMOP, which is a more open standard than SDTM and uses a stricter model with strict implementation guides. 

This Community Forum event will take place over Zoom on 12 April 2023, 14:00–15:00(BST)/09:00–10:00 (EST). 


Presenter Bio 

Image Added

Berber Snoeijer, ClinLine

Berber Snoeijer started in clinical research in 1997 as a biometrician and has since then worked with clinical data in different functions. In 2001 she started a CRO – Biometric Support – aimed at the data management, data analysis and reporting of clinical trials. In 2011 she started as an R&D manager dedicated to investigating and utilising the potential of real-world data from electronic health records. This resulted in many different solutions including a full reporting system to give feedback information to clinical research professionals. Berber is experienced with software and database engineering, process engineering and improving efficient utilisation and interaction of people based on management drivers. Nowadays, she uses these skills and knowledge to help life science companies assess, design and improve business solutions and processes at smaller and larger scales.

Image Modified

Mary Anne Rutkowski, Merk & Co

Mary Anne Rutkowski is currently a Principal Scientist at Merck & Co in a Statistical Programming department, where her team provides high-quality programming analysis and reporting deliverables using real-world-data for non-interventional studies. She has been at Merck for over 30 years and during her first 25 years she had many roles, most of which were in programming groups that used clinical trial data for regulatory submissions or claims data for marketing analysis. Mary Anne recently joined the PHUSE Real-World Evidence Working Group. She has a bachelor’s degree in engineering, a master’s degree in computer science and a master’s degree in business administration.


Jerry Wang, Johnson & Johnson 


Mike Briganti, Johnson & Johnson 


Kimberly Greene, PPD